IQV vs. ROIV: IQVIA vs. Roivant Sciences Stock Comparison

November 11, 2026

How do IQVIA (IQV) and Roivant Sciences (ROIV) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

IQVIA (IQV) and Roivant Sciences (ROIV) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but IQV is classified in Life Sciences Tools & Services while ROIV is classified in Biotechnology.

Company profile comparison for IQVIA (IQV) and Roivant Sciences (ROIV)
Profile Item	IQV	ROIV
Name	IQVIA Holdings Inc.	Roivant Sciences Ltd.
Country/Region	United States	United Kingdom
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	44.80 billion USD	28.08 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	May 9, 2013	December 8, 2020
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

IQV

ROIV

GSPC

IQVIA (IQV) vs. Roivant Sciences (ROIV), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for IQVIA (IQV) and Roivant Sciences (ROIV). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for IQVIA (IQV) and Roivant Sciences (ROIV). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for IQVIA (IQV) and Roivant Sciences (ROIV)
Metric	IQV	ROIV
Total Return (1Y)	32.11%	96.75%
Total Return (3Y, Annualized)	13.15%	68.04%
Total Return (5Y, Annualized)	2.00%	36.73%

Risk Profile

Drawdown History

IQV

ROIV

GSPC

IQVIA (IQV) vs. Roivant Sciences (ROIV), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for IQVIA (IQV) and Roivant Sciences (ROIV). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for IQVIA (IQV) and Roivant Sciences (ROIV)
Metric	IQV	ROIV
Volatility (1Y, Annualized)	40.77%	47.99%
Beta (5Y)	1.14	1.17
Max Drawdown (5Y)	-51.52%	-79.22%
Avg. Volume (3M)	1.40M	7.82M

Risk-Adjusted Performance

Risk-Return Positioning

IQV and ROIV are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for IQVIA (IQV) and Roivant Sciences (ROIV)
Metric	IQV	ROIV
Sharpe Ratio (1Y)	0.68	1.93
Sortino Ratio (1Y)	1.03	4.03

Profitability

ROE (TTM)

Roivant Sciences (ROIV) reports a negative ROE of -8.52%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile IQVIA (IQV) reports 21.39%, ranking against industry peers normally.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.39%

Max: 109.18%
IQV: 21.39%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.52%

Max: 109.18%
Q3: 6.23%
ROIV: -8.52%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

IQVIA (IQV) vs. Roivant Sciences (ROIV): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

IQVIA (IQV) at 8.05% retains a top-quartile share of revenue as profit, ahead of Roivant Sciences (ROIV) at 0.00%, which keeps about the industry-typical share.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.05%

Max: 18.05%
IQV: 8.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
ROIV: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

IQVIA (IQV) vs. Roivant Sciences (ROIV): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile IQVIA (IQV) reports 13.73%, ranking against industry peers normally.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.73%

Max: 83.12%
Q3: 14.77%
IQV: 13.73%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-25,408.11%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
ROIV: -25,408.11%

IQVIA (IQV) vs. Roivant Sciences (ROIV): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for IQVIA (IQV) and Roivant Sciences (ROIV)
Metric	IQV	ROIV
ROE (TTM)	21.39%	-8.52%
ROA (TTM)	5.08%	-16.28%
Net Margin (TTM)	8.05%	0.00%
Operating Margin (TTM)	13.73%	-25,408.11%
Gross Margin (TTM)	33.07%	0.00%

Growth

Revenue Growth

IQVIA (IQV) at 5.87% is around its peer norm for revenue growth, while Roivant Sciences (ROIV) at -71.57% drops into the bottom quartile, signaling weaker demand or pricing momentum.

IQVIA (IQV) vs. Roivant Sciences (ROIV): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: IQVIA (IQV) reports EPS growth of 4.67%, ranked against its industry; Roivant Sciences (ROIV) has no EPS growth figure this period.

IQVIA (IQV) vs. Roivant Sciences (ROIV): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for IQVIA (IQV) and Roivant Sciences (ROIV)
Metric	IQV	ROIV
Revenue Growth (YoY)	5.87%	-71.57%
Revenue Growth (3Y CAGR)	4.21%	-36.01%
EPS Growth (YoY)	4.67%	--
EPS Growth (3Y CAGR)	11.08%	--

Financial Strength

Current Ratio (MRQ)

Roivant Sciences (ROIV) at 16.72 carries current ratio above its industry’s typical mid-range, while IQVIA (IQV) at 0.83 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
IQV: 0.83
Min: 0.10

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.72

Max: 25.13
ROIV: 16.72
Q3: 12.13
Median: 5.52
Q1: 2.47
Min: 0.10

IQVIA (IQV) vs. Roivant Sciences (ROIV): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Roivant Sciences (ROIV) at 0.02 is near its industry mid-range for debt-to-equity ratio, while IQVIA (IQV) at 2.40 sits above its benchmark range, pointing to a heavier debt load relative to equity.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40

IQV: 2.40
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max: 1.42
Q3: 0.65
Median: 0.15
ROIV: 0.02
Q1: 0.02
Min: 0.00

IQVIA (IQV) vs. Roivant Sciences (ROIV): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for IQVIA (IQV) and Roivant Sciences (ROIV)
Metric	IQV	ROIV
Current Ratio (MRQ)	0.83	16.72
Debt / Equity (MRQ)	2.40	0.02
Net Debt / EBITDA	4.46	--

Dividends

Dividend Yield (TTM)

Neither IQVIA (IQV) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

IQV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

IQVIA (IQV) vs. Roivant Sciences (ROIV): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither IQVIA (IQV) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

IQV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

IQVIA (IQV) vs. Roivant Sciences (ROIV): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for IQVIA (IQV) and Roivant Sciences (ROIV)
Metric	IQV	ROIV
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: IQVIA (IQV) trades at 33.07 times trailing earnings, ranked against its peers, while Roivant Sciences (ROIV) has no P/E ratio this period.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.07

Max: 85.34
Q3: 43.46
IQV: 33.07
Median: 26.69
Q1: 13.30
Min: 0.07

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
ROIV: --

IQVIA (IQV) vs. Roivant Sciences (ROIV): ROIV does not report P/E ratio, so it has no value marker; IQV is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

IQVIA (IQV) at 2.59 sits in the cheaper P/S ratio quartile while Roivant Sciences (ROIV) at 3,728.61 prices above its industry range — a wide gap in sales valuation between them.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.59

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
IQV: 2.59
Min: 0.01

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

3,728.61

ROIV: 3,728.61
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

IQVIA (IQV) vs. Roivant Sciences (ROIV): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both IQVIA (IQV) at 6.73 and Roivant Sciences (ROIV) at 6.64 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.73

Max: 13.53
IQV: 6.73
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.64

Max: 13.53
ROIV: 6.64
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

IQVIA (IQV) vs. Roivant Sciences (ROIV): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for IQVIA (IQV) and Roivant Sciences (ROIV)
Metric	IQV	ROIV
P/E Ratio (TTM)	33.07	--
P/S Ratio (TTM)	2.59	3,728.61
P/B Ratio (MRQ)	6.73	6.64
Free Cash Flow Yield (TTM)	4.72%	-3.98%